Patients with both RA and metabolic syndrome demonstrated lower response rates to TNF inhibitor and non-TNF inhibitor therapies.

Fatigue was independently associated with the development of D2T RA, despite it not being included in the formal definition.

New research has pinpointed key cells that could be targeted to prevent painful rheumatoid arthritis flare-ups, offering ...

‘Poly-refractory’ disease affects 2.7% of patients with rheumatoid arthritis (RA) who have failed different groups of biologic disease-modifying antirheumatic drugs (b-DMARDS) and targeted synthetic ...